Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1426 participants.
Also called NCT02943785
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,426 participants
- Sponsor
- Registry
-
NCT02943785 -
2016-003930-26
-
- Other papers using this trial's data
- Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial
- Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02943785. Randomized; no masking; primary purpose treatment. Start 2017-03-21 (actual); primary completion 2021-02-28 (actual). Results posted on 2022-03-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Edoxaban-based Regimen
- Intervention (Drug)
- VKA-based Regimen
- Lead sponsor
- Daiichi Sankyo
- Collaborator
- Chiltern International Inc.
Record details
- Record id
cardio:ct-nct02943785- Content hash
d47b07637500765d3fb6cddb42ba84cb636138ccc0a2364d5857a0a528892acf